{
  "symbol": "REGN",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1991,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.467
  },
  "top_positive": [
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 857.8 $ 849.4 Regeneron's share of collaboration profit from sales outside the United States $ 333.6 $ 350.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.3) (16.6) Regeneron's share of profits $ 317.3 $ 333.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 37% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue decreased for the three months ended March\u00a031, 2025, compared to the same period in 2024, primarily due to lower reimbursements for manufacturing commercial supplies as a result of timing of shipments, partially offset by higher royalties and share of profits earned\nuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate.",
      "score": 0.9911
    },
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 857.8 $ 849.4 Regeneron's share of collaboration profit from sales outside the United States $ 333.6 $ 350.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.3) (16.6) Regeneron's share of profits $ 317.3 $ 333.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 37% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue decreased for the three months ended March\u00a031, 2025, compared to the same period in 2024, primarily due to lower reimbursements for manufacturing commercial supplies as a result of timing of shipments, partially offset by higher royalties and share of profits earned in connection with license agreements.",
      "score": 0.9869
    },
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 857.8 $ 849.4 Regeneron's share of collaboration profit from sales outside the United States $ 333.6 $ 350.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.3) (16.6) Regeneron's share of profits $ 317.3 $ 333.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 37% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue decreased for the\nopment and commercialization of product candidates for a target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.",
      "score": 0.986
    }
  ],
  "top_negative": [
    {
      "sent": "The side effects previously reported for Dupixent include severe allergic reactions, eye problems (including eye pain or changes in vision), joint aches and pain, parasitic (helminth) infections, facial rash or redness, and inflammation of blood vessels in the skin; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions that may occur in any organ system or tissue, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea.",
      "score": -0.9628
    },
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "We and our collaborators and contract manufacturers would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.",
      "score": -0.9531
    }
  ],
  "forward_snippets": [
    "Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures .",
    "January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements.",
    "Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures .",
    "January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements.",
    "government and government agency obligations 4,820\nguidance related to improvements to income tax disclosures ."
  ],
  "curated_text": "Symbol: REGN. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 857.8 $ 849.4 Regeneron's share of collaboration profit from sales outside the United States $ 333.6 $ 350.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.3) (16.6) Regeneron's share of profits $ 317.3 $ 333.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 37% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue decreased for the three months ended March\u00a031, 2025, compared to the same period in 2024, primarily due to lower reimbursements for manufacturing commercial supplies as a result of timing of shipments, partially offset by higher royalties and share of profits earned\nuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate. Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 857.8 $ 849.4 Regeneron's share of collaboration profit from sales outside the United States $ 333.6 $ 350.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.3) (16.6) Regeneron's share of profits $ 317.3 $ 333.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 37% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue decreased for the three months ended March\u00a031, 2025, compared to the same period in 2024, primarily due to lower reimbursements for manufacturing commercial supplies as a result of timing of shipments, partially offset by higher royalties and share of profits earned in connection with license agreements. Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2025 2024 EYLEA 8 mg and EYLEA net product sales outside the United States $ 857.8 $ 849.4 Regeneron's share of collaboration profit from sales outside the United States $ 333.6 $ 350.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (a) (16.3) (16.6) Regeneron's share of profits $ 317.3 $ 333.9 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 37% 39% (a) See \"Collaboration, License, and Other Agreements - Bayer\" above for additional details on our contingent reimbursement obligation Other Revenue Other revenue decreased for the\nopment and commercialization of product candidates for a target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target. Top negative sentences: The side effects previously reported for Dupixent include severe allergic reactions, eye problems (including eye pain or changes in vision), joint aches and pain, parasitic (helminth) infections, facial rash or redness, and inflammation of blood vessels in the skin; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions that may occur in any organ system or tissue, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea. Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. We and our collaborators and contract manufacturers would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems. Forward-looking snippets: Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures . January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements. Recently Issued Accounting Standards Standard/Description Effective Date Impact of Adoption on the Company's Financial Statements ASU 2023-09: In December 2023, the FASB issued amended guidance related to improvements to income tax disclosures . January 1, 2025 No significant impact expected ASU 2024-03: In November 2024, the FASB issued new guidance which requires disclosure of disaggregated income statement expense information about specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) in the notes to financial statements. government and government agency obligations 4,820\nguidance related to improvements to income tax disclosures ."
}